欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (9): 1004-1009.doi: 10.12092/j.issn.1009-2501.2022.09.007

• 药物治疗学 • 上一篇    下一篇

急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察

庞胜峰1,张晶2,吴宁宁1,李茹1,曹军1,何胜虎2   

  1. 1泰州市中医院心血管病科,泰州 225300;2江苏省苏北人民医院心内科,扬州 225002
  • 收稿日期:2022-05-16 修回日期:2022-08-20 出版日期:2022-09-27 发布日期:2022-10-14
  • 通讯作者: 何胜虎,男,硕士,主任医师,研究方向:冠心病及心脏重症的介入治疗、经导管主动脉瓣置换术。 E-mail: yzhshys@163.com
  • 作者简介:庞胜峰,男,硕士,副主任医师,研究方向:冠状动脉介入治疗和心脏起搏器置入术。 E-mail: psf936@163.com
  • 基金资助:
    江苏省卫生健康委科研课题(Z2018032)

Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI

PANG Shengfeng1, ZHANG Jing2, WU Ningning1, LI Ru1, CAO Jun1, HE Shenghu2   

  1. 1Department of Cardiology, Taizhou Hospital of Traditional Chinese Medicine, Taizhou 225300, Zhejiang, China; 2Department of Cardiology, Subei People's Hospital of Jiangsu Province, Yangzhou 225002, Jiangsu, China
  • Received:2022-05-16 Revised:2022-08-20 Online:2022-09-27 Published:2022-10-14

摘要: 目的:观察经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)的急性冠脉综合征(acute coronary syndrome, ACS)患者短程双联抗栓后单用替格瑞洛抗血小板治疗的临床疗效。方法:选取2018年10月至2021年12月我院及江苏省苏北人民医院接受过PCI术的ACS患者172例,根据患者服药情况分为3组:A组(单纯替格瑞洛组)50例;B组(阿司匹林肠溶片+替格瑞洛组)62例;C组(阿司匹林肠溶片+硫酸氢氯吡格雷组)60例。观察患者术后再发心绞痛、支架内再狭窄、再次血运重建、心衰、出血等情况。结果:3组之间术后再发心绞痛、支架内再狭窄、再次血运重建、心衰、出血无统计学差异。结论:PCI术后短程双抗后单用替格瑞洛抗血小板治疗患者缺血性事件、心衰无增加,而且可减少出血风险。

关键词: 经皮冠状动脉介入治疗, 替格瑞洛, 急性冠脉综合征, 缺血性事件, 出血

Abstract:

AIM: To observe the clinical efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI).  METHODS: A total of 172 patients with ACS who had undergone PCI from October 2018 to April 2022 in our hospital and Subei People's Hospital of Jiangsu Province were selected and divided into three groups according to the patients' medication status: 50 patients in group A (tegretol alone group); 62 patients in group B (aspirin enteric coated tablets + tegretol group); and 60 patients in group C (aspirin enteric coated tablets + clopidogrel hydrogen sulfate group). The patients were observed for postoperative recurrent angina pectoris, in-stent restenosis, revascularization, heart failure, and bleeding. RESULTS: There were no significant differences in postoperative recurrent angina, in-stent restenosis, re-hematologic reconstruction, heart failure, and bleeding between the 3 groups. CONCLUSION: There is no increase in ischemic events, heart failure in patients treated with tegretol antiplatelet therapy alone after a short course of dual antibiotics after PCI and it reduces risk of bleeding.

Key words: percutaneous coronary intervention, ticagrelor, acute coronary syndrome, ischemic events, bleeding 

中图分类号: